Literature DB >> 18095015

Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra.

Eleni Mylona1, Styliani Golfinopoulou, Michael Samarkos, Panagiotis Fanourgiakis, Vasilios Papadakos, Athanasios Skoutelis.   

Abstract

Adult onset Still's disease (AOSD) is a well-recognized clinical disorder characterized by involvement of various organs, including liver. However, acute hepatitis or hepatic failure is extremely rare, and most of the reported cases occurred during treatment with hepatotoxic drugs. Anakinra is an interleukin-1 receptor antagonist (IL-1Ra). Experimental and clinical data support a central role for IL-1Ra in fulminant hepatic failure. We report the case of a patient with AOSD complicated with acute hepatitis during treatment with corticosteroids, which was dramatically improved with anakinra.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18095015     DOI： 10.1007/s10067-007-0791-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   3.650


  15 in total

1.  Successful living related liver transplantation for adult Still's disease.

Authors:  Junichi Yamanaka; Shinichi Saito; Nobukazu Kuroda; Tadamichi Hirano; Jiro Fujimoto
Journal:  J Gastroenterol Hepatol       Date:  2003-09       Impact factor: 4.029

2.  Refractory adult onset Still's disease successfully treated with anakinra.

Authors:  F M Vasques Godinho; M J Parreira Santos; J Canas da Silva
Journal:  Ann Rheum Dis       Date:  2004-09-16       Impact factor: 19.103

3.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

4.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease.

Authors:  Avril A Fitzgerald; Sharon A Leclercq; Alexander Yan; Joanne E Homik; Charles A Dinarello
Journal:  Arthritis Rheum       Date:  2005-06

5.  Still's disease in the adult.

Authors:  E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-03       Impact factor: 19.103

6.  Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.

Authors:  Masahiro Shinoda; Arno W Tilles; Go Wakabayashi; Atsushi Takayanagi; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  Tissue Eng       Date:  2006-05

7.  Adult Still's disease: manifestations, disease course, and outcome in 62 patients.

Authors:  J Pouchot; J S Sampalis; F Beaudet; S Carette; F Décary; M Salusinsky-Sternbach; R O Hill; A Gutkowski; M Harth; D Myhal
Journal:  Medicine (Baltimore)       Date:  1991-03       Impact factor: 1.889

8.  Adult Still's disease. Evolution of a clinical syndrome and diagnosis, treatment, and follow-up of 17 patients.

Authors:  E B Larson
Journal:  Medicine (Baltimore)       Date:  1984-03       Impact factor: 1.889

9.  Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

Authors:  Marc Michel; Cristophe Duvoux; Cristophe Hezode; Daniel Cherqui
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

10.  Fulminant hepatic failure in adult onset Still's disease.

Authors:  O Dino; G Provenzano; G Giannuoli; E Sciarrino; M Pouyet; L Pagliaro
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666
View more
  9 in total

1.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

2.  [IL-1 antagonists].

Authors:  I Kötter; G Horneff
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

Review 3.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 4.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

5.  Severe hyperferritinemia--a clue for severe hepatitis in a patient with adult-onset Still's disease.

Authors:  Rema Bishara; Yolanda Braun-Moscovici; Amir Dagan; Kohava Toledano; Tarek Saadi; Edmond Sabo; Alexandra Balbir-Gurman
Journal:  Clin Rheumatol       Date:  2014-11-22       Impact factor: 3.650

6.  Anakinra Hepatotoxicity in a Patient With Adult-Onset Still's Disease.

Authors:  Osman Ahmed; Mayur Brahmania; Majid Alsahafi; Saad Alkhowaiter; Sig Erb
Journal:  ACG Case Rep J       Date:  2015-04-10

7.  Rare Manifestation of a Rare Disease, Acute Liver Failure in Adult Onset Still's Disease: Dramatic Response to Methylprednisolone Pulse Therapy-A Case Report and Review.

Authors:  Nalini Valluru; Venkata S Tammana; Michael Windham; Eyasu Mekonen; Rehana Begum; Andrew Sanderson
Journal:  Case Rep Med       Date:  2014-06-04

Review 8.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711

9.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.